Umecrine Cognition AB

Umecrine Cognition AB is a Swedish biotech startup that focuses on developing a groundbreaking drug to treat cognitive disorders resulting from various underlying diseases. The company's most advanced drug candidate, golexanolone, has shown promising results in improving brain signaling, cognition, and alertness in patients with hepatic encephalopathy, as highlighted in an internationally recognized clinical phase 2 study. Founded in 2006, the company recently received a kr30.40M investment through a Convertible Note from AB Ility, Ribbskottet, and Karolinska on 17 November 2023. Umecrine Cognition's innovative approach in addressing neurological disorders positions it within the intersection of Biotechnology, Health Care, and the Pharmaceutical industry. The company's initial focus is on patients with symptoms related to chronic liver disease, while the potential mechanism of action holds relevance for various other indication areas. With a vision to transform the landscape of cognitive disorder treatment, Umecrine Cognition is poised to make significant strides within the pharmaceutical and healthcare sectors.